Peptide Encyclopaedia
Cibinetide (ARA-290)
Also known as ARA-290.
Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.
Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.
At-a-glance profile
- Classification
- Innate-repair receptor peptide (investigational)
- Approval status
- Investigational · Not approved for human use
- Research status
- Investigational / reference listing.
- Molecular formula
- Insufficient reliable evidence identified.
- Molecular weight
- Insufficient reliable evidence identified.
- Sequence
- 11-amino-acid EPO-derived peptide without erythropoietic activity in design intent.
- Primary biological target
- Insufficient reliable evidence identified.
- Half-life
- Insufficient reliable evidence identified.
- Routes investigated
- Insufficient reliable evidence identified.
- Human evidence level
- C — Limited or early human evidence
What is it?
Investigational neuropathy/repair peptide. Not EPO. Not sold.
Mechanism of action
Proposed IRAK/innate repair receptor signalling.
Not an approved EPO substitute.
What is it being studied for?
- Sarcoid neuropathy and other programmes
Investigational findings are not proven clinical benefits unless an authority has labelled that indication.
Evidence level
Overall human evidence grade: C · Limited or early human evidence
Human research
Clinical development; not a shop medicine.
Preclinical research
Animal, cell and in-vitro findings are listed separately from human effects.
Tissue-repair models.
Doses reported in published research
This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.
Doses reported in human studies
Insufficient reliable evidence identified.
Preclinical / animal study dosing
Insufficient reliable evidence identified.
Pharmacokinetics
Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.
Safety
As per trials; unregulated vials unsafe.
Unknowns. Absence of a published harm signal is not evidence of safety.
Contraindications. Not for unapproved use.
Regulatory status
Investigational.
Educational.
Citations
[1] Encyclopaedia note
Encyclopaedia note
For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.
Last reviewed 2026-09-13. Research areas: Recovery · Compare peptides